Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


















Authors
 

BURROUGH WEL Fact Sheet, BURROUGH WEL Financial Results - Equitymaster

Jan 18, 2022 | Updated on Jan 18, 2022

Check out BURROUGH WEL fact sheet and BURROUGH WEL financial results online at Equitymaster.

Burroughs Wellcome net down 38%

Oct 31, 2000

Burroughs Wellcome has reported disappointing results for the third quarter ended September 2000. While sales have dropped 18% the net profit has fallen by more than 38%.

Burroughs Wellcome: Following Glaxo's footsteps

Jul 26, 2000

Burroughs Wellcome has followed Glaxo's footsteps in declaring impressive second quarter results. While turnover has increased 22.9%, the bottomline has jumped more than 35%.

Burroughs Wellcome: Results reflective of continuing domestic slowdown

Apr 26, 2000

Burroughs Wellcome has a relatively older product range vis–a-Glaxo. Quite a few products such as Septran, Actified, Banocide have actually shown a degrowth last year ranging from 6 to 10%. The trend seems to be continuing in the first quarter of the current year as evidenced by the 2.7% growth in the topline.

Burroughs Wellcome posts 8% jump in net

Oct 27, 1999

Burroughs Wellcome has posted a 7.5% growth in net sales and a 8% growth in profits for the quarter ending 30th September 1999. The 30% growth in income and the 33% decline in interest expenditure has enabled the bank to marginally improve its net margins.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS